Affordable Access

deepdyve-link
Publisher Website

Targeting Bcl-2 for cancer therapy.

Authors
  • Zhang, Linlin1
  • Lu, Zaiming2
  • Zhao, Xiangxuan3
  • 1 Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, LN, China. , (China)
  • 2 Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, LN, China. Electronic address: [email protected] , (China)
  • 3 Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, LN, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Biochimica et biophysica acta. Reviews on cancer
Publication Date
Aug 01, 2021
Volume
1876
Issue
1
Pages
188569–188569
Identifiers
DOI: 10.1016/j.bbcan.2021.188569
PMID: 34015412
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Apoptosis deficiency is one of the most important features observed in neoplastic diseases. The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis regulators. Research and clinical studies have both demonstrated that the hyperactivation of Bcl-2-related anti-apoptotic effects correlates with cancer occurrence, progression and prognosis, also having a role in facilitating the radio- and chemoresistance of various malignancies. Therefore, targeting Bcl-2 inactivation has provided some compelling therapeutic advantages by enhancing apoptotic sensitivity or reversing drug resistance. Therefore, this pharmacological route turned into one of the most promising routes for cancer treatment. This review discusses some of the well-defined and emerging roles of Bcl-2 as well as its potential clinical value in cancer therapeutics. Copyright © 2021 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times